Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

Impact · against what's priced in

The selection of Qureight's Fibr8™ imaging biomarker as a secondary endpoint for the PROPEL-IPF trial is a positive incremental step for Contineum Therapeutics. It reduces clinical risk by providing quantitative data to support Phase 2 results, potentially streamlining the transition to Phase 3.

CTNM+0.30: No priced-in read yet

Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

What matters in this story

How each ticker is affected

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

What matters in this story

How each ticker is affected

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

Track these names every morning.

3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

What matters in this story

How each ticker is affected

Next reads from the same story arc

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

What matters in this story

How each ticker is affected

Next reads from the same story arc

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

Track these names every morning.

3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines